Cystic fibrosis is caused by an inherited mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Due to this mutation, the CFTR protein doesn’t embed in cell membranes to form a channel for chlorine ions the way it should. As a result, mucus-producing cells secrete a thicker-than-normal mucus that can create blockages in the lungs and… Read More »
FDA Approves Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Cystic Fibrosis Patients Ages 12 and Older Who Have at Least One F508del Mutation Print this page BOSTON–(BUSINESS WIRE)–Oct. 21, 2019– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF)… Read More »
Researchers say a drug that is already available on the market can help those affected by cystic fibrosis. An antifungal medication may help people with cystic fibrosis. Amphotericin, which is an antifungal medication, might help people with cystic fibrosis fight the chronic bacterial lung infections that tend to occur with this disease, according to a… Read More »
The Pulmonary Fibrosis Foundation has launched its first phase of a patient registry with 2,000 patients on board. The foundation also is inviting researchers to submit proposals to access data from the registry, which could aid in understanding the causes of pulmonary fibrosis, ways to help doctors improve diagnoses and discover new treatments. Pulmonary fibrosis… Read More »